Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Financing Activities (2023 - 2025)

CG Oncology filings provide 3 years of Cash from Financing Activities readings, the most recent being $99.1 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 55.66% to $99.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $153.6 million, a 75.55% decrease, with the full-year FY2025 number at $153.6 million, down 75.55% from a year prior.
  • Cash from Financing Activities hit $99.1 million in Q4 2025 for CG Oncology, up from $54.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $402.7 million in Q1 2024 to a low of -$15.2 million in Q2 2023.
  • Median Cash from Financing Activities over the past 3 years was $1.3 million (2024), compared with a mean of $72.4 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 52735.03% in 2024 and later plummeted 840.0% in 2025.
  • CG Oncology's Cash from Financing Activities stood at -$2.9 million in 2023, then soared by 7814.57% to $223.4 million in 2024, then tumbled by 55.66% to $99.1 million in 2025.
  • The last three reported values for Cash from Financing Activities were $99.1 million (Q4 2025), $54.4 million (Q3 2025), and -$296000.0 (Q2 2025) per Business Quant data.